References
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54.
Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55 Suppl 3:S1–13.
Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578–86.
Gertz MA. Managing tumor lysis syndrome in 2010. Leuk Lymphoma. 2010;51:179–80.
Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006;18:773–80.
Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014;6(5):222–8.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.
Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93(12):1877–85.
Frestad D, Perner A, Pedersen UG. Acute onset and rapid progression of multiple organ failure in a young adult with undiagnosed disseminated colonic adenocarcinoma. BMJ Case Rep. 2014;24:2014.
Nikolic-Tomasevic Z, Jelic S, Popov I, Radosavljevic D. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction. J Chemother. 2000;12:244–51.
Boisseau M, Bugat R, Mahjoubi M. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11). Eur J Cancer. 1996;32:737–8.
Kim HD, Ha KS, Woo IS, Jung YH, Han CW, Kim TJ. Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with 5-fluorouracil/leucovorin and oxaliplatin: case report and literature review. Cancer Res Treat. 2014;46(2):204–7.
Hentrich M, Schiel X, Scheidt B, Reitmeier M, Hoffmann U, Lutz L. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer. Acta Oncol. 2008;47:155–6.
Krishnan G, D’Silva K, Al-Janadi A. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol. 2008;26:2406–8.
Oztop I, Demirkan B, Yaren A, Tarhan O, Sengul B, Ulukus C, et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan. Tumori. 2004;90:514–6.
Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am J Med Sci. 2003;325(1):38–40.
Patterson DJ, Dew EW, Gyorkey F, Graham DY. Niacin hepatitis. South Med J. 1983;76:239–41.
Pye E, Northcote RJ, Cobbe SM. Acute hepatitis after parenteral amiodarone administration. Br Heart J. 1988;59:690–1.
Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol. 2009;15(35):4464–6.
Shiozawa K, Watanabe M, Takenaka H, Nagai H, Ishii K, Sakai K, et al. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology. 2010;57(101):688–90.
Conflicts of Interest
The authors report no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Farooqi, B., Simmons, J. & Hao, Z. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib. J Gastrointest Canc 46, 314–316 (2015). https://doi.org/10.1007/s12029-015-9711-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-015-9711-6